ArticleEpigenetics2016
Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
Article in Epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.Nutrition and cancer · 2019Trial
- Suppression of MCP-1, IFN-γ and IL-6 production of HNSCCFrontiers in immunology · 2024Article
- Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group.Frontiers in oncology · 2024Review
- Effect of Marital Status on Upper Digestive Tract Tumor Survival: Married Male Patients Exhibited a Better Prognosis.Frontiers in surgery · 2022Article
- Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.Virologica Sinica · 2021Review
- Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.Journal of ovarian research · 2021Article
- Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Review
- Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.BMC cancer · 2020Article
- Review
- Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.Bioscience reports · 2020Article
- Development and verification of a personalized immune prognostic feature in breast cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.Oncology reports · 2020Article
- Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma.PeerJ · 2020Article
- Characterization of a prognostic four‑gene methylation signature associated with radiotherapy for head and neck squamous cell carcinoma.Molecular medicine reports · 2019Article
- Laryngeal Preservation Approaches: Considerations for New Selection Criteria Based on the DeLOS-II Trial.Frontiers in oncology · 2019Review
- [Update on HPV-associated head and neck cancer-highlights of the 2018 ASCO Annual Meeting].HNO · 2018Review
- [HPV - A different view on Head and Neck Cancer].Laryngo- rhino- otologie · 2018Review
- Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients.Frontiers in oncology · 2018Article
- PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9%) and a low prevalence of HPV16-related tumors (8.8%) was analyzed by MassARRAY to determine a previously established prognostic methylation score (MS). Kaplan-Meier revealed a highly significant correlation between a high MS and a favorable survival for OPSCC (P = 0.0004) and for non-OPSCC (P<0.0001), which was confirmed for all HNSCC by multivariate Cox regression models (HR: 9.67, 95% CI [4.61-20.30], P<0.0001). Next, we established a minimal methylation signature score (MMSS), which consists of ten most informative of the originally 62 CpG units used for the MS. The prognostic value of the MMSS was confirmed by Kaplan-Meier analysis for all HNSCC (P<0.0001) and non-OPSCC (P = 0.0002), and was supported by multivariate Cox regression models for all HNSCC (HR: 2.15, 95% CI [1.36-3.41], P = 0.001). In summary, the MS and the MMSS exhibit an excellent performance as prognosticators for survival, which is not limited by the anatomical site, and both could be implemented in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.